Hrmy.O

Harmony Biosciences Holdings maintains a conservative capital structure with a debt-to-equity ratio of 0.17, indicating limited leverage relative to its equity base. The company holds substantial liquidity, with cash and equivalents totaling $752.5 million against total liabilities of $401.4 million, resulting in a low liquidity risk assessment. The balance sheet shows total assets of $1.27 billion and total equity of $870.2 million, providing a solid foundation for operations.

Profitability metrics demonstrate strong returns, with a return on equity of 16.73% and a return on assets of 11.45%. The company generated $868.5 million in revenue and $158.7 million in net income, yielding a net margin of approximately 18.3%. Operating income stands at $208.5 million, reflecting efficient cost management relative to gross profit of $670.1 million.

Segment and geographic revenue breakdowns are not provided in the available data, preventing an analysis of revenue concentration or regional exposure. The company's valuation multiples include a price-to-earnings ratio of 14.18 and an EV/EBITDA of 7.68, suggesting a moderate valuation relative to earnings.

Growth trajectory analysis is limited due to the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue and net income, but no year-over-year or quarterly trends are available to assess momentum.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company's cash position of $752.5 million significantly exceeds its long-term debt of $143.7 million, further mitigating financial distress risks.

Recent observations include analyst estimates with a mean price target of $45.40 and a median of $44.00, reflecting a positive outlook from market participants. The mean recommendation is 2.40, with five buy ratings and three hold ratings, indicating moderate bullish sentiment. No significant news events or filing observations were reported beyond system reconciler activities.

Revenue $215.4M, +16,6% YoY; Operating income −33,7% YoY.

• ▍Revenue $215.4M, +16,6% YoY
• ▍Operating income −33,7% YoY
• ▍Net income −28,7% YoY
• ▍Free cash flow −25,2% YoY
• ▍Net margin 15.1%

Revenue $243.8M, +21,1% YoY; Operating income −30,8% YoY.

• ▍Revenue $243.8M, +21,1% YoY
• ▍Operating income −30,8% YoY
• ▍Net income −54,5% YoY
• ▍Free cash flow −80,8% YoY
• ▍Net margin 9.2%

Revenue $239.5M, +28,7% YoY; Operating income +6,1% YoY.

• ▍Revenue $239.5M, +28,7% YoY
• ▍Operating income +6,1% YoY
• ▍Net income +10,3% YoY
• ▍Free cash flow +9,0% YoY
• ▍Net margin 21.2%

Revenue $200.5M, +16,0% YoY; Operating income +125,6% YoY.

• ▍Revenue $200.5M, +16,0% YoY
• ▍Operating income +125,6% YoY
• ▍Net income +243,2% YoY
• ▍Free cash flow +168,9% YoY
• ▍Net margin 19.8%

Revenue $184.7M; Operating income $56.2M.

• ▍Revenue $184.7M
• ▍Operating income $56.2M
• ▍Net margin 24.7%

Revenue $201.3M; Operating income $55.7M.

• ▍Revenue $201.3M
• ▍Operating income $55.7M
• ▍Net margin 24.6%

Revenue $186.0M; Operating income $61.7M.

• ▍Revenue $186.0M
• ▍Operating income $61.7M
• ▍Net margin 24.8%

Revenue $172.8M; Operating income $21.4M.

• ▍Revenue $172.8M
• ▍Operating income $21.4M
• ▍Net margin 6.7%

Revenue $868.5M, +21,5% YoY; Operating income +9,2% YoY.

• ▍Revenue $868.5M, +21,5% YoY
• ▍Operating income +9,2% YoY
• ▍Net income +9,1% YoY
• ▍Free cash flow −2,4% YoY
• ▍Net margin 18.3%

Revenue $714.7M, +22,8% YoY; Operating income +4,7% YoY.

• ▍Revenue $714.7M, +22,8% YoY
• ▍Operating income +4,7% YoY
• ▍Net income +12,9% YoY
• ▍Free cash flow +10,2% YoY
• ▍Net margin 20.4%

Revenue $582.0M, +32,9% YoY; Operating income +51,6% YoY.

• ▍Revenue $582.0M, +32,9% YoY
• ▍Operating income +51,6% YoY
• ▍Net income −29,0% YoY
• ▍Free cash flow −7,2% YoY
• ▍Net margin 22.1%

Revenue $437.9M, +43,4% YoY; Operating income +95,8% YoY.

• ▍Revenue $437.9M, +43,4% YoY
• ▍Operating income +95,8% YoY
• ▍Net income +424,5% YoY
• ▍Free cash flow +451,4% YoY
• ▍Net margin 41.4%